Ultragenyx Buy Rating Reiterated while DTX301 Trial Reduces Ammonia, Stock Falls 3.46%
Bank of America maintained its Buy rating for Ultragenyx, noting an undervalued pipeline with shares trading at $21.44 after a 3.46% drop. Late-stage trial data for DTX301 demonstrated effective ammonia reduction in OTC deficiency patients, boosting confidence in potential market impact and its 2.07 billion market capitalization.
1. Rating Reiteration by Bank of America
Bank of America maintained its Buy rating for Ultragenyx, emphasizing that its gene therapy pipeline remains undervalued. The firm cited the potential of DTX301 and other product candidates as justification for its positive stance.
2. DTX301 Late-Stage Trial Results
Late-stage trial data for DTX301 showed meaningful reduction of blood ammonia levels in patients with ornithine transcarbamylase deficiency. These results strengthen the therapy’s commercial outlook and support regulatory discussions.
3. Stock Performance and Market Metrics
Shares traded between $21.12 and $22.29 before closing at $21.44, down 3.46%, reflecting market volatility after the trial announcement. Ultragenyx’s market capitalization stands at approximately 2.07 billion with average trading volume around 544,561 shares.